• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于临床试验建议系统的知识工程:揭示方案规范中的错误

Knowledge engineering for a clinical trial advice system: uncovering errors in protocol specification.

作者信息

Musen M A, Rohn J A, Fagan L M, Shortliffe E H

出版信息

Bull Cancer. 1987;74(3):291-6.

PMID:3620734
Abstract

ONCOCIN is an expert system that provides advice to physicians who are treating cancer patients enrolled in clinical trials. The process of encoding oncology protocol knowledge for the system has revealed serious omissions and unintentional ambiguities in the protocol documents. We have also discovered that many protocols allow for significant latitude in treating patients and that even when protocol guidelines are explicit, physicians often choose to apply their own judgment on the assumption that the specifications are incomplete. Computer-based tools offer the possibility of insuring completeness and reproducibility in the definition of new protocols. One goal of our automated protocol authoring environment, called OPAL, is to help physicians develop protocols that are free of ambiguity and thus to assure better compliance and standardization of care.

摘要

ONCOCIN是一个专家系统,它为治疗参加临床试验的癌症患者的医生提供建议。为该系统编码肿瘤学方案知识的过程揭示了方案文件中存在的严重遗漏和无意的歧义。我们还发现,许多方案在治疗患者方面有很大的灵活性,而且即使方案指南很明确,医生也常常基于规范不完整的假设而选择运用自己的判断。基于计算机的工具为确保新方案定义的完整性和可重复性提供了可能性。我们名为OPAL的自动化方案编写环境的一个目标是帮助医生制定没有歧义的方案,从而确保更好的依从性和护理标准化。

相似文献

1
Knowledge engineering for a clinical trial advice system: uncovering errors in protocol specification.用于临床试验建议系统的知识工程:揭示方案规范中的错误
Bull Cancer. 1987;74(3):291-6.
2
The use of high-fidelity human patient simulation as an evaluative tool in the development of clinical research protocols and procedures.在临床研究方案和程序的制定过程中,使用高保真人体患者模拟作为一种评估工具。
Contemp Clin Trials. 2005 Dec;26(6):646-59. doi: 10.1016/j.cct.2005.09.004. Epub 2005 Oct 14.
3
Cancer clinical trials in the USA: patient eligibility, generalizability of results and technology transfer.美国的癌症临床试验:患者资格、结果的可推广性及技术转让
Bull Cancer. 1987;74(2):197-203.
4
The NCI All Ireland Cancer Conference.美国国家癌症研究所全爱尔兰癌症会议。
Oncologist. 1999;4(4):275-277.
5
Surgeons: A Future Role in Clinical Trials?外科医生:在临床试验中未来会扮演何种角色?
Oncologist. 1997;2(3):V-VI.
6
Clinical trial accrual among new cancer patients at a community-based cancer center.一家社区癌症中心新确诊癌症患者的临床试验入组情况。
Cancer. 2006 Jan 15;106(2):426-33. doi: 10.1002/cncr.21597.
7
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites.美国临床肿瘤学会关于临床试验场所最低标准和示范属性的声明。
J Clin Oncol. 2008 May 20;26(15):2562-7. doi: 10.1200/JCO.2007.15.6398. Epub 2008 Apr 7.
8
A collaborative clinical trial protocol writing system.一种协作式临床试验方案撰写系统。
Stud Health Technol Inform. 2004;107(Pt 2):1481-6.
9
Monitoring clinical research. A report from the Childrens Cancer Study Group.监测临床研究。儿童癌症研究组的一份报告。
Am J Clin Oncol. 1984 Oct;7(5):557-66.
10
Design and endpoints of clinical trials in hepatocellular carcinoma.肝细胞癌临床试验的设计与终点
J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13.

引用本文的文献

1
The IMPACT framework and implementation for accessible in silico clinical phenotyping in the digital era.数字时代可访问的计算机临床表型分析的IMPACT框架与实施
NPJ Digit Med. 2023 Jul 21;6(1):132. doi: 10.1038/s41746-023-00878-9.
2
Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment.不可切除的 III 期非小细胞肺癌患者的真实世界历程:疾病分期与治疗的当前困境
J Clin Med. 2022 Mar 21;11(6):1738. doi: 10.3390/jcm11061738.
3
A knowledge base of clinical trial eligibility criteria.临床试验入选标准知识库。
J Biomed Inform. 2021 May;117:103771. doi: 10.1016/j.jbi.2021.103771. Epub 2021 Apr 1.
4
Criteria2Query: a natural language interface to clinical databases for cohort definition.Criteria2Query:一种用于定义队列的临床数据库自然语言接口。
J Am Med Inform Assoc. 2019 Apr 1;26(4):294-305. doi: 10.1093/jamia/ocy178.
5
The representativeness of eligible patients in type 2 diabetes trials: a case study using GIST 2.0.2型糖尿病试验中符合条件患者的代表性:一项使用GIST 2.0的案例研究
J Am Med Inform Assoc. 2018 Mar 1;25(3):239-247. doi: 10.1093/jamia/ocx091.
6
GIST 2.0: A scalable multi-trait metric for quantifying population representativeness of individual clinical studies.GIST 2.0:一种用于量化个体临床研究人群代表性的可扩展多特征指标。
J Biomed Inform. 2016 Oct;63:325-336. doi: 10.1016/j.jbi.2016.09.003. Epub 2016 Sep 4.
7
Correlating eligibility criteria generalizability and adverse events using Big Data for patients and clinical trials.利用大数据关联患者和临床试验的资格标准普遍性及不良事件。
Ann N Y Acad Sci. 2017 Jan;1387(1):34-43. doi: 10.1111/nyas.13195. Epub 2016 Sep 6.
8
Trend and Network Analysis of Common Eligibility Features for Cancer Trials in ClinicalTrials.gov.ClinicalTrials.gov上癌症试验常见合格特征的趋势与网络分析。
Smart Health. 2014 Jul;8549:130-141. doi: 10.1007/978-3-319-08416-9_13.
9
Optimizing Clinical Research Participant Selection with Informatics.利用信息学优化临床研究参与者的选择
Trends Pharmacol Sci. 2015 Nov;36(11):706-709. doi: 10.1016/j.tips.2015.08.007.
10
Knowledge representation and tool support for critiquing clinical trial protocols.用于审查临床试验方案的知识表示与工具支持。
Proc AMIA Symp. 2000:724-8.